MedWatch

IO Biotech begins phase III trial with partner MSD

IO Biotech joins forces with partner MSD in the development of a new therapy for the treatment of skin cancer in combination with IO Biotech's lead candidate Keytruda. A big phase III trial now commences, and if successful, IO Biotech maintains commercial rights.

Photo: ANDREAS GEBERT/REUTERS / X06742

A possible breakthrough in the treatment of metastatic melanoma patients could be on the way. Around 290,000 people are diagnosed with the skin cancer every year.

The Danish cancer company IO Biotech has just entered into a partnership with the US pharmaceutical giant MSD. Together, they will develop a potential treatment against the serious cancer.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs